Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

Completed · Phase 1

Conditions studied: Chronic Lymphocytic Leukemia, Richter Syndrome

In brief

The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.

Key facts

Study ID

NCT02535286

Run by

TG Therapeutics, Inc.

People needed

27

Starts

2015-09-18

Expected to finish

2021-11-04

Last updated by the study team

2022-10-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia or Richter's Transformation
• Refractory to or relapsed after at least 1 prior treatment regimen
• Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

You may not qualify if…

• Any major surgery, chemotherapy or immunotherapy within the last 14 days
• Known hepatitis B virus, hepatitis C virus or HIV infection
• Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP)

Where it is running

• TG Therapeutics Investigational Trial Site — New York, New York, United States
• TG Therapeutics Investigational Trial Site — Durham, North Carolina, United States
• TG Therapeutics Investigational Trial Site — Philadelphia, Pennsylvania, United States
• TG Therapeutics Investigational Trial Site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.